NEW YORK (GenomeWeb News) - Rosetta Genomics and New York University Medical Center said today that they plan to co-develop diagnostic tests for lung and mesothelioma cancers.
The early-detection tests will use Rosetta's technology for extracting microRNA from blood.
The tests will identify patients at risk of lung cancer due to smoking as well as those who have been exposed to asbestos fibers.
"MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers," said Harvey Pass, chief of NYU Medical Center's Thoracic Surgery and Thoracic Oncology divisions, in a statement.
Financial terms of the agreement were not released.